Yang W, et al. - In this 26-week, phase 3 trial, researchers evaluated the effectiveness and tolerability of twice-daily (BID) IDegAsp vs biphasic insulin aspart 30 (BIAsp 30) BID, both ± metformin, in 543 Chinese subjects with type 2 diabetes partially controlled on premix/self-mix or basal insulin ± metformin. With IDegAsp BID vs BIAsp 30 BID, they calculated that the rates of nocturnal confirmed and total confirmed hypoglycemic episodes were 47% and 43% lower, respectively. They observed a greater likelihood of cases to reach HbA1c < 7.0% (< 53 mmol/mol) without confirmed hypoglycemia with IDegAsp BID vs BIAsp 30 BID.